Table 2 Basic characteristics of the patients.

From: Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis

characteristics

Wang30

Ge31

Ueno16

Ohkawa15

S-1 Co (n = 28)

S-1 Mo (n = 30)

S-1 Co (n = 45)

S-1 Mo (n = 47)

S-1 Co (n = 69)

S-1 Mo (n = 71)

S-1 Co (n = 134)

S-1 Mo (n = 130)

Age, yr

 Median

62

48

57

58

65

64

65

63.5

 Rang

40–76

40–65

36–76

30–76

NA

NA

27–83

43–80

Others, No. (%)

 Male

15(53.6)

16(53.3)

26(57.8)

35(74.5)

41(59.4)

38(53.5)

82(61.2)

80(61.5)

ECOG score

 0

7(25.0)

8(26.7)

NA

NA

45(65.2)

48(67.6)

93(69.4)

92(70.8)

 1

10(35.7)

9(30.0)

NA

NA

24(34.8)

23(32.4)

41(30.6)

38(29.2)

 2

11(39.3)

13(43.3)

0(0)

0(0)

0(0)

0(0)

0(0)

0(0)

BSA, m2

 <1.25

NA

NA

NA

NA

3(4.3)

2(2.8)

8(6.0)

6(4.6)

 1.25–1.5

NA

NA

NA

NA

28(40.6)

28(39.4)

53(39.6)

51(39.2)

 >1.5

NA

NA

NA

NA

38(55.1)

41(57.8)

73(54.4)

73(56.2)

Primary tumor site

 head

22(78.6)

23(76.7)

19(42.2)

21(44.7)

NA

NA

38(28.4)

34(26.2)

 others

6(22.4)

7(23.3)

26(57.8)

26(55.3)

NA

NA

106(71.6)

106(73.8)

pancreatectomy

 Yes

NA

NA

21(46.7)

21(44.7)

13(18.8)

24(33.8)

NA

NA

 No

NA

NA

24(53.3)

26(55.3)

56(81.2)

47(66.2)

NA

NA